De Gaulle Fleurance advises AlphaRose Therapeutics on the acquisition of Alpha Anomeric SA
De Gaulle Fleurance assisted US company AlphaRose Therapeutics with its first acquisition in Europe, that of biotech Alpha Anomeric SA.
Based in Austin, Texas, AlphaRose Therapeutics was founded in 2024 by Casey McPherson. It develops and markets treatments for neurogenetic developmental diseases.
For its part, Alpha Anomeric is a French company, founded in 2018, that has developed a novel proprietary oligonucleotide chemistry platform (abcDNA), a patented technology that may be exploited by the US company.
AlphaRose Therapeutics was advised in the United States by Faber Law (Ken Itrato, Maria Bergenhem), and in France by Jean-Christophe Amy and Jean-Marie Job, partners, and Charlotte Hébert-Salomon, senior counsel at De Gaulle Fleurance.
"We are delighted to have supported AlphaRose Therapeutics in its external growth project in Europe,"
"This acquisition of Alpha Anomeric will contribute to the development of new models for the rapid development of treatments for rare diseases”.
Counsels
About us
De Gaulle Fleurance is a leading player in business law. It supports its clients in both advisory and litigation matters, in France and abroad, with:
- 200 people dedicated to client relationships built on excellence, responsiveness, and creativity;
- A full-service practice assisting businesses and public entities with their structural developments (mergers and acquisitions, corporate and project financing…) and their operational activities (commercial contracts, public procurement, joint ventures…);
- An expertise recognized by the business community (Chambers, The Legal 500, Best Lawyers);
- A presence in Paris, Brussels, Geneva, Abu Dhabi and Abidjan;
- An international culture and the ability to mobilize a network of correspondents across all continents.
Press contacts :
Constance Baudry, +33 (0)6 82 43 69 62,
constance.baudry@agence-constance.fr
Sarah Maouchi, +33 (0)7 57 76 83 97,
sarah.maouchi@agence-constance.fr
